%0 Journal Article
%A Baertsch, Marc-Andrea
%A Mai, Elias K
%A Hielscher, Thomas
%A Bertsch, Uta
%A Salwender, Hans J
%A Munder, Markus
%A Fuhrmann, Stephan
%A Dührsen, Ulrich
%A Brossart, Peter
%A Neben, Kai
%A Schlenzka, Jana
%A Kunz, Christina
%A Raab, Marc S
%A Hillengaß, Jens
%A Jauch, Anna
%A Seckinger, Anja
%A Hose, Dirk
%A Luntz, Steffen
%A Sonneveld, Pieter
%A Lokhorst, Henk
%A Martin, Hans
%A Goerner, Martin
%A Hoffmann, Martin
%A Lindemann, Hans-Walter
%A Bernhard, Helga
%A Blau, Igor W
%A Scheid, Christof
%A Besemer, Britta
%A Weisel, Katja C
%A Hänel, Mathias
%A Dürig, Jan
%A Goldschmidt, Hartmut
%T Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
%J Blood cancer journal
%V 11
%N 1
%@ 2044-5385
%C London [u.a.]
%I Nature Publishing Group
%M DKFZ-2021-00064
%P 1
%D 2021
%X Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1-21 of 28 day cycles) followed by 10-15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33414374
%R 10.1038/s41408-020-00390-3
%U https://inrepo02.dkfz.de/record/166717